TP53 Arg72Pro polymorphism and colorectal cancer risk: A systematic review and meta-analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 7, 2010, Pages 1840-1847

  Dahabreh, Issa J ^a   Linardou, Helena ^b   Bouzika, Peggy ^c   Varvarigou, Vasileia ^c   Murray, Samuel ^d  

^a TUFTS MEDICAL CENTER   (United States)

^b First Department of Medical Oncology Metropolitan Hospital   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d Greek Society for Molecular Oncology (EIEMO)   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; B RAF KINASE; DNA GLYCOSYLASE MUTY; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE; POPULATION RESEARCH; PRIORITY JOURNAL; SKIN CANCER; WILD TYPE; CASE CONTROL STUDY; COLORECTAL TUMOR; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; RISK; RISK FACTOR;

CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954511773     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0156     Document Type: Article

References (66)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009;59:225-49.
2. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
3. Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002;137:603-12.
4. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
5. Sager R. Tumor suppressor genes: the puzzle and the promise. Science 1989;246:1406-12.
6. Xu H, el-Gewely MR. P53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol Annu Rev 2001;7:131-64.
7. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-6.
8. Meek DW. The p53 response to DNA damage. DNA Repair (Amst) 2004;3:1049-56.
9. Frebourg T, Friend SH. Cancer risks from germline p53 mutations. J Clin Invest 1992;90:1637-41.
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
11. Gomez-Lazaro M, Fernandez-Gomez FJ, Jordan J. p53: twenty five years understanding the mechanism of genome protection. J Physiol Biochem 2004;60:287-307.
12. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003; 21:271-6.
13. Soong R, Powell B, Elsaleh H, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000;36:2053-60.
14. Delattre O, Olschwang S, Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;2:353-6.
15. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244: 217-21.
16. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-3. (Pubitemid 17004567)
17. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100. (Pubitemid 29046852)
18. Irwin MS. Family feud in chemosensitvity: p73 and mutant p53. Cell Cycle 2004;3:319-23.
19. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25:47-54.
20. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
21. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
22. Zhou Y, Li N, Zhuang W, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 2007;121: 1481-6.
23. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009;9:95-107.
24. Klug SJ, Ressing M, Koenig J, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 2009;10:772-84.
25. Dai S, Mao C, Jiang L, Wang G, Cheng H. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum Genet 2009;125:633-8.
26. Chen J, Etzel CJ, Amos CI, et al. Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome. Cancer Causes Control 2009;20:1769-77.
27. Available from: http://geneticassociationdb.nih.gov/; last accessed: July 31, 2009.
28. Available from: http://www-p53.iarc.fr/; last accessed: July 31, 2009.
29. Available from: http://p53.free.fr/; last accessed: July 31, 2009.
30. Cochran W. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
33. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995;48:45-57; discussion 9-60.
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. (Pubitemid 27387172)
35. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary end points. Stat Med 2006;25:3443-57.
36. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219.
37. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JP. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol 2006;163:300-9.
38. Goodman JE, Mechanic LE, Luke BT, Ambs S, Chanock S, Harris CC. Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer 2006;118:1790-7.
39. Gaustadnes M, Orntoft TF, Jensen JL, Torring N. Validation of the use of DNA pools and primer extension in association studies of sporadic colorectal cancer for selection of candidate SNPs. Hum Mutat 2006;27:187-94.
40. Mammano E, Belluco C, Bonafe M, et al. Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol 2009;35:415-9.
41. Cao Z, Song JH, Park YK, et al. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 2009;56:114-8.
42. Csejtei A, Tibold A, Varga Z, et al. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res 2008;28:1917-22.
43. Dakouras A, Nikiteas N, Papadakis E, et al. P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Res 2008; 28:1039-43.
44. Gemignani F, Moreno V, Landi S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004;23:1954-6.
45. Grünhage F, Jungck M, Lamberti C, et al. Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis 2008;23:147-54.
46. Hamajima N, Matsuo K, Suzuki T, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002; 181:81-5.
47. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14:1085-9. (Pubitemid 23193532)
48. Koushik A, Tranah GJ, Ma J, et al. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006;119:1863-8.
49. Kruger S, Bier A, Engel C, et al. The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). J Med Genet 2005;42:769-73.
50. Langerod A, Bukholm IR, Bregard A, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002;11:1684-8.
51. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996; 17:261-4.
52. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet 1991;86:369-70.
53. Perez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006;12:1426-9.
54. Perfumo C, Bonelli L, Menichini P, et al. Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-72 haplotype. Digestion 2006;74:228-35.
55. Polakova V, Pardini B, Naccarati A, et al. Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum Mutat 2009;30:661-8.
56. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001;109:25-34.
57. Schneider-Stock R, Mawrin C, Motsch C, et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 2004;164: 1233-41.
58. Sjalander A, Birgander R, Athlin L, et al. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995;16:1461-4.
59. Sotamaa K, Liyanarachchi S, Mecklin JP, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005;11:6840-4.
60. Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, Chang-Claude J. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? Pharmacogenet Genomics 2007;17:639-45.
61. Webb EL, Rudd MF, Sellick GS, et al. Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives. Hum Mol Genet 2006;15: 3263-71.
62. Zhu ZZ, Wang AZ, Jia HR, et al. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 2007;37:385-90.
63. Ioannidis JP, Ntzani EE, Trikalinos TA. "Racial" differences in genetic effects for complex diseases. Nat Genet 2004;36:1312-8.
64. Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JP. Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med 2005;2:e334.
65. Brooks LA, Tidy JA, Gusterson B, et al. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 2000;60:6875-7. (Pubitemid 32059156)
66. Tada M, Furuuchi K, Kaneda M, et al. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001;22:515-7. (Pubitemid 32203833)